BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 2009;374:1606-16. [DOI: 10.1016/s0140-6736(09)61375-1] [Cited by in Crossref: 708] [Cited by in F6Publishing: 613] [Article Influence: 54.5] [Reference Citation Analysis]
Number Citing Articles
1 Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology 2022;163:1198-1225. [DOI: 10.1053/j.gastro.2022.08.045] [Reference Citation Analysis]
2 Park S, Oh S, Kim E. Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice. Journal of Biological Chemistry 2022. [DOI: 10.1016/j.jbc.2022.102682] [Reference Citation Analysis]
3 Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, Li R. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.925377] [Reference Citation Analysis]
4 Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab 2022. [PMID: 36254579 DOI: 10.1111/dom.14863] [Reference Citation Analysis]
5 Meijer JL, Roderka MN, Chinburg EL, Renier TJ, Mcclure AC, Rothstein RI, Barry EL, Billmeier S, Gilbert-diamond D. Alterations in Fecal Short-Chain Fatty Acids after Bariatric Surgery: Relationship with Dietary Intake and Weight Loss. Nutrients 2022;14:4243. [DOI: 10.3390/nu14204243] [Reference Citation Analysis]
6 Chiu M, Moist L, Al-Jaishi A, Jain AK. Recognition of Obesity and Perceptions of Weight Loss Management in Patients With Chronic Kidney Disease: A Retrospective Cross-Sectional Study. Can J Kidney Health Dis 2022;9:20543581221129465. [PMID: 36246343 DOI: 10.1177/20543581221129465] [Reference Citation Analysis]
7 Vosoughi K, Salman Roghani R, Camilleri M. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. Obesity Medicine 2022;35:100456. [DOI: 10.1016/j.obmed.2022.100456] [Reference Citation Analysis]
8 Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. BMC Endocr Disord 2022;22:241. [PMID: 36175881 DOI: 10.1186/s12902-022-01140-1] [Reference Citation Analysis]
9 Koldemir Gündüz M, Kaymak G, Kanbur E, Berikten D, Şener H. Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis. Toxicol In Vitro 2022;85:105479. [PMID: 36152787 DOI: 10.1016/j.tiv.2022.105479] [Reference Citation Analysis]
10 Holmbäck U, Grudén S, Litorp H, Willhems D, Kuusk S, Alderborn G, Söderhäll A, Forslund A. Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial. Obesity (Silver Spring) 2022. [PMID: 36123783 DOI: 10.1002/oby.23557] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Liao Y, Chen H, Yang C, Lee P, Hsu C, Huang Y, Yang T. Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. Front Pharmacol 2022;13:978814. [DOI: 10.3389/fphar.2022.978814] [Reference Citation Analysis]
12 Wu Q, Li D, Huang C, Zhang G, Wang Z, Liu J, Yu H, Song B, Zhang N, Li B, Chu X. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomedicine & Pharmacotherapy 2022;153:113517. [DOI: 10.1016/j.biopha.2022.113517] [Reference Citation Analysis]
13 Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:298. [PMID: 36031641 DOI: 10.1038/s41392-022-01149-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wu W, Zhou Q, Yuan P, Qiao D, Deng S, Cheng H, Ren Y. A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients. Diabetes Metab Syndr Obes 2022;15:2521-34. [PMID: 35999869 DOI: 10.2147/DMSO.S365192] [Reference Citation Analysis]
15 Ganawa S, Santhosh SH, Parry L, Syed AA. Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome. Clin Obes 2022;:e12546. [PMID: 35932204 DOI: 10.1111/cob.12546] [Reference Citation Analysis]
16 Utzschneider KM, Ehrmann DA, Arslanian SA, Barengolts E, Buchanan TA, Caprio S, Edelstein SL, Hannon TS, Kahn SE, Kozedub A, Mather KJ, Nadeau KJ, Sam S, Tripputi M, Xiang AH, El Ghormli L; RISE Consortium. Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring) 2022;30:1579-88. [PMID: 35894078 DOI: 10.1002/oby.23475] [Reference Citation Analysis]
17 Blonde L, Umpierrez GE, Reddy SS, Mcgill JB, Berga SL, Bush M, Chandrasekaran S, Defronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Agius R, Coelho C, Mcgowan B. GLP-1 analogues in clinical management of obesity. Current Opinion in Endocrine and Metabolic Research 2022;25:100360. [DOI: 10.1016/j.coemr.2022.100360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Pileggi CA, Hooks BG, McPherson R, Dent RRM, Harper ME. Targeting skeletal muscle mitochondrial health in obesity. Clin Sci (Lond) 2022;136:1081-110. [PMID: 35892309 DOI: 10.1042/CS20210506] [Reference Citation Analysis]
20 Jeong D, Priefer R. Anti-obesity weight loss medications: Short-term and long-term use. Life Sci 2022;306:120825. [PMID: 35870619 DOI: 10.1016/j.lfs.2022.120825] [Reference Citation Analysis]
21 Palani A, Nawrocki AR, Orvieto F, Bianchi E, Mandić E, Pessi A, Huang C, Deng Q, Toussaint N, Walsh E, Reddy V, Ashley E, He H, Mumick S, Hawes B, Marsh D, Erion M, Nargund R, Carrington PE. Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R, Wang HHX. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis. International Journal of Clinical Practice 2022;2022:1-14. [DOI: 10.1155/2022/1201977] [Reference Citation Analysis]
23 Sharma A, Albhaisi S, Sanyal AJ. Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health. Clinical Liver Disease. [DOI: 10.1002/cld.1219] [Reference Citation Analysis]
24 Deng Y, Park A, Zhu L, Xie W, Pan CQ. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Ther Adv Chronic Dis 2022;13:20406223221108064. [PMID: 35813188 DOI: 10.1177/20406223221108064] [Reference Citation Analysis]
25 Douton JE, Acharya NK, Stoltzfus B, Sun D, Grigson PS, Nyland JE. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behav Pharmacol 2022. [PMID: 35695511 DOI: 10.1097/FBP.0000000000000685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Jensterle M, Rizzo M, Haluzík M, Janež A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther 2022;39:2452-67. [PMID: 35503498 DOI: 10.1007/s12325-022-02153-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Taha MB, Yahya T, Satish P, Laird R, Agatston AS, Cainzos-Achirica M, Patel KV, Nasir K. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Curr Atheroscler Rep 2022. [PMID: 35624390 DOI: 10.1007/s11883-022-01041-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Kumar N, D'Alessio DA. Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss. J Clin Endocrinol Metab 2022:dgac276. [PMID: 35536590 DOI: 10.1210/clinem/dgac276] [Reference Citation Analysis]
29 Ranjit R, Alexandrovna Lapik I, Minkailovna Gapparova K, Vladimirovich Galchenko A. Bariatric Surgery. Nutr Today 2022;57:117-144. [DOI: 10.1097/nt.0000000000000540] [Reference Citation Analysis]
30 Stier C, Koschker A, Kim M, Stier R, Chiappetta S, Stein J. Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity – A proof of concept study. Clinical Nutrition ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.05.009] [Reference Citation Analysis]
31 Le TDV, Liu D, Ellis BJ, Collins S, Ayala JE. Glucagon-Like Peptide-1 Receptor Activation Stimulates PKA-Mediated Phosphorylation of Raptor and this Contributes to the Weight Loss Effects of Liraglutide.. [DOI: 10.1101/2022.04.21.489078] [Reference Citation Analysis]
32 Barritt AS 4th, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther 2022;55:944-59. [PMID: 35266164 DOI: 10.1111/apt.16794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
33 Falardeau J. New Options (or not) for Treatment of Idiopathic Intracranial Hypertension. Curr Neurol Neurosci Rep 2022. [PMID: 35332515 DOI: 10.1007/s11910-022-01188-5] [Reference Citation Analysis]
34 Chen X, Huang W, Wei D, Zhao JP, Zhang W, Ding DG, Jiao Y, Pan HL, Zhang JJ, Zhong F, Gao F, Jin YT, Zheng YW, Zhang YJ, Huang Q, Zeng XT, Zhou ZY. Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial. Evid Based Complement Alternat Med 2022;2022:4780019. [PMID: 35265146 DOI: 10.1155/2022/4780019] [Reference Citation Analysis]
35 Wretlind A, Zobel EH, de Zawadzki A, Ripa RS, Curovic VR, von Scholten BJ, Mattila IM, Hansen TW, Kjær A, Vestergaard H, Rossing P, Legido-quigley C. Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Front Clin Diabetes Healthc 2022;3. [DOI: 10.3389/fcdhc.2022.856485] [Reference Citation Analysis]
36 Douton JE, Horvath N, Mills-Huffnagle S, Nyland JE, Hajnal A, Grigson PS. Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addict Biol 2022;27:e13117. [PMID: 34802173 DOI: 10.1111/adb.13117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
37 Liu Y, Luo X. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. Front Med . [DOI: 10.1007/s11684-021-0873-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Nicolau J, Ayala L, Bonet A, Manga B, Muñoz JM, Olea J, Gil A. GLP1 analogues among patients with overweight or obesity during lockdown. Medicina Clínica (English Edition) 2022;158:105-110. [DOI: 10.1016/j.medcle.2020.12.038] [Reference Citation Analysis]
39 Elhag W, El Ansari W. Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes. OBES SURG. [DOI: 10.1007/s11695-021-05884-y] [Reference Citation Analysis]
40 Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Shaunik A, Yoon KH. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care 2022;10:e002207. [PMID: 35042751 DOI: 10.1136/bmjdrc-2021-002207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Evers SS, Shao Y, Ramakrishnan SK, Shin JH, Bozadjieva-Kramer N, Irmler M, Stemmer K, Sandoval DA, Shah YM, Seeley RJ. Gut HIF2α signaling is increased after VSG, and gut activation of HIF2α decreases weight, improves glucose, and increases GLP-1 secretion. Cell Rep 2022;38:110270. [PMID: 35045308 DOI: 10.1016/j.celrep.2021.110270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Elbelt U, Berger H, Hofmann T. Conservative Treatment of Obesity. Obesity and Metabolic Surgery 2022. [DOI: 10.1007/978-3-662-63227-7_2] [Reference Citation Analysis]
43 Roberts A, Phuah P, Cheng S, Murphy KG. Targeting Enteroendocrine Cells to Treat Metabolic Disease. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00068-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Markantes GK, Tsichlia G, Georgopoulos NA. Diet and exercise in the management of PCOS: Starting from the basics. Polycystic Ovary Syndrome 2022. [DOI: 10.1016/b978-0-12-823045-9.00010-9] [Reference Citation Analysis]
45 May M, Jordan J. Medikamentöse Therapie der Adipositas. Handbuch Essstörungen und Adipositas 2022. [DOI: 10.1007/978-3-662-63544-5_76] [Reference Citation Analysis]
46 Jagasia S, Hendrickson CD, Williams AJ. Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus. Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch15] [Reference Citation Analysis]
47 Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the Treatment of Obesity. Trends Cardiovasc Med 2021:S1050-1738(21)00158-4. [PMID: 34942372 DOI: 10.1016/j.tcm.2021.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Vosoughi K, Atieh J, Khanna L, Khoshbin K, Prokop LJ, Davitkov P, Murad MH, Camilleri M. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. EClinicalMedicine 2021;42:101213. [PMID: 34877513 DOI: 10.1016/j.eclinm.2021.101213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Bauri R, Bele S, Edelli J, Reddy NC, Kurukuti S, Devasia T, Ibrahim A, Rai V, Mitra P. I-M-150847, a novel GLP-1 and GIP receptor dual agonist, improves glycemic control and reduces obesity in the rodent model of type 2 diabetes and obesity.. [DOI: 10.1101/2021.12.05.471325] [Reference Citation Analysis]
50 Napoli R, Avogaro A, Formoso G, Piro S, Purrello F, Targher G, Consoli A. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutr Metab Cardiovasc Dis 2021;31:3257-70. [PMID: 34627692 DOI: 10.1016/j.numecd.2021.08.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
51 Kohut T, Panganiban J. Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus. JPGN Reports 2021;2:e141. [DOI: 10.1097/pg9.0000000000000141] [Reference Citation Analysis]
52 Xue S, Han H, Rui S, Yang M, Huang Y, Zhan B, Geng S, Liu H, Chen C, Yang G, Li L. Serum Fetuin-B Levels Are Elevated in Women with Metabolic Syndrome and Associated with Increased Oxidative Stress. Oxid Med Cell Longev 2021;2021:6657658. [PMID: 34646426 DOI: 10.1155/2021/6657658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ruska Y, Szilvásy-Szabó A, Kővári D, Kádár A, Mácsai L, Sinkó R, Hrabovszky E, Gereben B, Fekete C. Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice. Brain Struct Funct 2021. [PMID: 34596755 DOI: 10.1007/s00429-021-02380-y] [Reference Citation Analysis]
54 Douton JE, Acharya NK, Stoltzfus B, Sun D, Grigson PS, Nyland JE. Acute Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Prevents Drug-Induced Heroin Seeking in Rats.. [DOI: 10.1101/2021.09.15.460527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hansen TT, Astrup A, Sjödin A. Are Dietary Proteins the Key to Successful Body Weight Management? A Systematic Review and Meta-Analysis of Studies Assessing Body Weight Outcomes after Interventions with Increased Dietary Protein. Nutrients 2021;13:3193. [PMID: 34579069 DOI: 10.3390/nu13093193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
56 Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiol Behav 2021;238:113456. [PMID: 33989649 DOI: 10.1016/j.physbeh.2021.113456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
57 Gao F, Wu D, Guo L, Wang L, Hao M, Li L, Ni D, Hao H. Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein. Ann Transl Med 2021;9:1157. [PMID: 34430598 DOI: 10.21037/atm-21-3094] [Reference Citation Analysis]
58 Hartinger JM. Novel drugs in pharmacotherapy of obesity. Prakticke lekarenstvi 2021;17:74-80. [DOI: 10.36290/lek.2021.015] [Reference Citation Analysis]
59 Nogueiras R. MECHANISMS IN ENDOCRINOLOGY: The gut-brain axis: regulating energy balance independent of food intake. Eur J Endocrinol 2021;185:R75-91. [PMID: 34260412 DOI: 10.1530/EJE-21-0277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
60 Tricò D, Solini A. Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice. Adv Chronic Kidney Dis 2021;28:328-36. [PMID: 34922689 DOI: 10.1053/j.ackd.2021.04.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Fortin SM, Lipsky RK, Lhamo R, Chen J, Kim E, Borner T, Schmidt HD, Hayes MR. GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats. Sci Transl Med 2020;12:eaay8071. [PMID: 32132220 DOI: 10.1126/scitranslmed.aay8071] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 42.0] [Reference Citation Analysis]
62 Moon S, Lee J, Chung HS, Kim YJ, Yu JM, Yu SH, Oh CM. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. Endocrinol Metab (Seoul) 2021;36:647-60. [PMID: 34139800 DOI: 10.3803/EnM.2020.934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
63 Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther 2021;38:2821-39. [PMID: 33977495 DOI: 10.1007/s12325-021-01710-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
64 Wang C, Hu HJ, Dong QQ, Huang R, Zhao W, Song YJ, Li ZY, Wang N, Zhang TC, Luo XG. Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide. Biosci Biotechnol Biochem 2021;85:1395-404. [PMID: 33784390 DOI: 10.1093/bbb/zbab053] [Reference Citation Analysis]
65 Ghazanfar H, Kandhi SD, Nawaz I, Javed N, Abraham MC, Farag M, Mahasamudram J, Patel VB, Altaf F, Patel H. Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. Cureus 2021;13:e15141. [PMID: 34164242 DOI: 10.7759/cureus.15141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
66 Pirlet C, Poirier P, Cieza T, Piché ME, Biertho L, Maes F, Ruzsa Z, Bertrand OF. Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiovasc Drugs 2021;21:271-81. [PMID: 32812206 DOI: 10.1007/s40256-020-00428-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines 2021;9:383. [PMID: 33916501 DOI: 10.3390/biomedicines9040383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
68 Bjørnholm KD, Ougaard ME, Skovsted GF, Knudsen LB, Pyke C. Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree. Endocrinol Diabetes Metab 2021;4:e00234. [PMID: 34277961 DOI: 10.1002/edm2.234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 van Son J, Koekkoek LL, La Fleur SE, Serlie MJ, Nieuwdorp M. The Role of the Gut Microbiota in the Gut-Brain Axis in Obesity: Mechanisms and Future Implications. Int J Mol Sci 2021;22:2993. [PMID: 33804250 DOI: 10.3390/ijms22062993] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
70 Casey R, Adelfio A, Connolly M, Wall A, Holyer I, Khaldi N. Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides. Biomedicines 2021;9:276. [PMID: 33803471 DOI: 10.3390/biomedicines9030276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
71 Lu VB, Gribble FM, Reimann F. Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion. Nutrients 2021;13:883. [PMID: 33803183 DOI: 10.3390/nu13030883] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
72 Dai Y, He H, Li S, Yang L, Wang X, Liu Z, An Z. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:622589. [PMID: 33664710 DOI: 10.3389/fendo.2020.622589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
73 Myat A, Redwood SR, Arri S, Gersh BJ, Bhatt DL, Marber MS. Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial. Diabetol Metab Syndr 2021;13:17. [PMID: 33579317 DOI: 10.1186/s13098-021-00635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab 2020;105:dgaa285. [PMID: 32442310 DOI: 10.1210/clinem/dgaa285] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 39.0] [Reference Citation Analysis]
75 Das G. Liraglutide for overweight and obesity. Pract Diab 2021;38:7. [DOI: 10.1002/pdi.2313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Koncz D, Tóth B, Roza O, Csupor D. A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss. Front Pharmacol 2020;11:611361. [PMID: 33574758 DOI: 10.3389/fphar.2020.611361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
77 Maor Y, Ergaz D, Malnick SDH, Melzer E, Neuman MG. Liraglutide-Induced Hepatotoxicity. Biomedicines 2021;9:106. [PMID: 33498980 DOI: 10.3390/biomedicines9020106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Park JH, Kim JY, Choi JH, Park HS, Shin HY, Lee JM, Kim JW, Ko HJ, Chon S, Kim BK, Kim CS, Lim S. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int J Obes (Lond) 2021;45:776-86. [PMID: 33473176 DOI: 10.1038/s41366-021-00739-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
79 Kansra AR, Lakkunarajah S, Jay MS. Childhood and Adolescent Obesity: A Review. Front Pediatr 2020;8:581461. [PMID: 33511092 DOI: 10.3389/fped.2020.581461] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 50.0] [Reference Citation Analysis]
80 Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? Clin Obes 2021;11:e12439. [PMID: 33423388 DOI: 10.1111/cob.12439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
81 Gorain B, Choudhury H, Sengupta P, Verma RK, Pandey M. Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity. Obesity and its Impact on Health 2021. [DOI: 10.1007/978-981-33-6408-0_10] [Reference Citation Analysis]
82 Abdul Salim S, Keri K, Agarwal M. Obesity. Textbook of Cardiorenal Medicine 2021. [DOI: 10.1007/978-3-030-57460-4_21] [Reference Citation Analysis]
83 Park K. Pharmacologic Treatment. A Strategic Approach to Knee Arthritis Treatment 2021. [DOI: 10.1007/978-981-16-4217-3_9] [Reference Citation Analysis]
84 Bele S, Girada SB, Ray A, Gupta A, Oruganti S, Prakash Babu P, Rayalla RS, Kalivendi SV, Ibrahim A, Puri V, Adalla V, Katika MR, DiMarchi R, Mitra P. MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice. Elife 2020;9:e52212. [PMID: 33349332 DOI: 10.7554/eLife.52212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
85 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
86 Svačina Š. Contemporary state and perspectives of obesity pharmacotherapy. Vnitr Lek 2020;66:478-482. [DOI: 10.36290/vnl.2020.143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Elbasan O, Sisman P, Peynirci H, Yabaci A, Ersoy C. Comparison Between Sleeve Gastrectomy and Exenatide on Type 2 Diabetic Patients. Bariatric Surgical Practice and Patient Care 2020;15:199-204. [DOI: 10.1089/bari.2019.0041] [Reference Citation Analysis]
88 Chen X, Huang W, Wei D, Ding DG, Jiao Y, Pan HL, Jin YT, Zheng YW, Zhang YJ, Zhang YR, Liu YR, Zhou ZY. Clinical effect of catgut implantation at acupoints for the treatment of simple obesity: A multicentre randomized controlled trial. Medicine (Baltimore) 2020;99:e23390. [PMID: 33235115 DOI: 10.1097/MD.0000000000023390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
89 Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (Torino) 2021;46:168-76. [PMID: 33213122 DOI: 10.23736/S2724-6507.20.03369-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
90 Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol 2021;18:291-304. [PMID: 33188304 DOI: 10.1038/s41569-020-00465-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 21.5] [Reference Citation Analysis]
91 Kim SH, Abbasi F, Nachmanoff C, Stefanakis K, Kumar A, Kalra B, Savjani G, Mantzoros CS. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes Obes Metab 2021;23:489-98. [PMID: 33140542 DOI: 10.1111/dom.14242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Chowdhury S, Goswami S. GLP1 agonists beyond glycemic control—redefining their role. Int J Diabetes Dev Ctries 2020;40:461-3. [DOI: 10.1007/s13410-020-00879-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102. [PMID: 33068776 DOI: 10.1016/j.molmet.2020.101102] [Cited by in Crossref: 156] [Cited by in F6Publishing: 174] [Article Influence: 78.0] [Reference Citation Analysis]
94 Liu H, Xu Y, Hu F. AMPK in the Ventromedial Nucleus of the Hypothalamus: A Key Regulator for Thermogenesis. Front Endocrinol (Lausanne) 2020;11:578830. [PMID: 33071984 DOI: 10.3389/fendo.2020.578830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
95 Chao AM, Wadden TA, Berkowitz RI, Quigley K, Silvestry F. The risk of cardiovascular complications with current obesity drugs. Expert Opin Drug Saf 2020;19:1095-104. [PMID: 32750250 DOI: 10.1080/14740338.2020.1806234] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
96 Kim YK, Kim OY, Song J. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front Pharmacol 2020;11:1270. [PMID: 32922295 DOI: 10.3389/fphar.2020.01270] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
97 Chou CA, Chuang SF. Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. J Diabetes Investig 2020;11:1524-31. [PMID: 32506681 DOI: 10.1111/jdi.13314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
98 Jalleh R, Pham H, Marathe CS, Wu T, Buttfield MD, Hatzinikolas S, Malbert CH, Rigda RS, Lange K, Trahair LG, Feinle-Bisset C, Rayner CK, Horowitz M, Jones KL. Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients 2020;12:E1962. [PMID: 32630191 DOI: 10.3390/nu12071962] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
99 Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Adv Drug Deliv Rev 2020;158:4-16. [PMID: 32592727 DOI: 10.1016/j.addr.2020.06.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 21.0] [Reference Citation Analysis]
100 Yang YM, Kuen DS, Chung Y, Kurose H, Kim SG. Gα12/13 signaling in metabolic diseases. Exp Mol Med 2020;52:896-910. [PMID: 32576930 DOI: 10.1038/s12276-020-0454-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
101 Schneider R, Kraljević M, Peterli R, Rohm TV, Klasen JM, Cavelti-Weder C, Delko T. GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. Obes Surg 2020;30:3561-9. [PMID: 32500274 DOI: 10.1007/s11695-020-04750-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Álvarez-mon M, Vaamonde JG, Biel A, Llavero-valero M. Actualización clínica de la obesidad y el sobrepeso. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:777-786. [DOI: 10.1016/j.med.2020.07.011] [Reference Citation Analysis]
103 Jones S, Hyde A, Davidson TL. Reframing appetitive reinforcement learning and reward valuation as effects mediated by hippocampal-dependent behavioral inhibition. Nutr Res 2020;79:1-12. [PMID: 32544728 DOI: 10.1016/j.nutres.2020.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
104 Hankir MK, Seyfried F. Do Bariatric Surgeries Enhance Brown/Beige Adipose Tissue Thermogenesis? Front Endocrinol (Lausanne) 2020;11:275. [PMID: 32425889 DOI: 10.3389/fendo.2020.00275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
105 Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, Taveras EM, Corey K, Kaplan L, Hur C. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2020;6:162-70. [PMID: 32313674 DOI: 10.1002/osp4.390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
106 Iepsen EW, Have CT, Veedfald S, Madsbad S, Holst JJ, Grarup N, Pedersen O, Brandslund I, Holm JC, Hansen T, Torekov SS. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Rep Med 2020;1:100006. [PMID: 33205056 DOI: 10.1016/j.xcrm.2020.100006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
107 Vally M. Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management. SAGP 2020. [DOI: 10.36303/sagp.2020.1.1.0006] [Reference Citation Analysis]
108 Fortin SM, Chen J, Hayes MR. Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide. Physiol Behav 2020;220:112870. [PMID: 32179053 DOI: 10.1016/j.physbeh.2020.112870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Godfrey C, Bremer A, Alba D, Apovian C, Koethe JR, Koliwad S, Lewis D, Lo J, McComsey GA, Eckard A, Srinivasa S, Trevillyan J, Palmer C, Grinspoon S. Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications. J Infect Dis 2019;220:420-31. [PMID: 30893434 DOI: 10.1093/infdis/jiz118] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 22.0] [Reference Citation Analysis]
110 Mitchell JL, Mollan SP, Vijay V, Sinclair AJ. Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. Curr Opin Neurol 2019;32:422-31. [PMID: 30865008 DOI: 10.1097/WCO.0000000000000690] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
111 Papathanasiou T, Strathe A, Agersø H, Lund TM, Overgaard RV. Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach. Diabetes Obes Metab 2020;22:969-77. [PMID: 32009288 DOI: 10.1111/dom.13985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Pydyn N, Miękus K, Jura J, Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep 2020;72:1-12. [PMID: 32016853 DOI: 10.1007/s43440-019-00020-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 19.5] [Reference Citation Analysis]
113 Chen S, Meyre D. An Update on Mendelian Forms of Obesity and their Personalized Treatments. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_16] [Reference Citation Analysis]
114 Potential cardiovascular benefits of GLP-1 analogues : evidence and implications for type 2 diabetes management. South African General Practitioner 2020;1:24-29. [DOI: 10.36303/sagp.2020.1.0006] [Reference Citation Analysis]
115 Wharton S, Liu A, Pakseresht A, Nørtoft E, Haase CL, Mancini J, Power GS, Vanderlelie S, Christensen RAG. Response to “Liraglutide Effectiveness: Is There a Real‐World Clinical Benefit?”. Obesity 2019;27:1728-1728. [DOI: 10.1002/oby.22630] [Reference Citation Analysis]
116 Li Z, Yang P, Liang Y, Xia N, Li Y, Su H, Pan H. Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway. Diabetes Metab Syndr Obes 2019;12:1697-703. [PMID: 31564937 DOI: 10.2147/DMSO.S216455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
117 Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci 2019;19:2591-9. [PMID: 32127832 DOI: 10.4314/ahs.v19i3.35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
118 Thangaraju P, Venkatesan S. Monotherapy with liraglutide - Points to be focussed. J Family Med Prim Care 2019;8:2551-2. [PMID: 31463296 DOI: 10.4103/jfmpc.jfmpc_435_19] [Reference Citation Analysis]
119 Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55. [PMID: 31470636 DOI: 10.3390/medicina55090546] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
120 Pratley RE, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KH. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes Obes Metab 2019;21:2429-39. [PMID: 31264757 DOI: 10.1111/dom.13824] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
121 He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, Dong Y, Sun J, Guo H, Williams KW. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. Mol Metab 2019;28:120-34. [PMID: 31446151 DOI: 10.1016/j.molmet.2019.07.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
122 van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Sci Rep 2019;9:9996. [PMID: 31292457 DOI: 10.1038/s41598-019-45593-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
123 van Eyk HJ, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol 2019;18:87. [PMID: 31288820 DOI: 10.1186/s12933-019-0890-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
124 Almarshad F. Short-term monotherapy with Liraglutide for weight management: A case study. J Family Med Prim Care 2019;8:1804-6. [PMID: 31198765 DOI: 10.4103/jfmpc.jfmpc_213_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
125 Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs 2018;78:1113-32. [PMID: 30014268 DOI: 10.1007/s40265-018-0946-y] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 21.3] [Reference Citation Analysis]
126 Hansen CS, Frandsen CS, Fleischer J, Vistisen D, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU, Dejgaard TF. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Front Endocrinol (Lausanne) 2019;10:242. [PMID: 31031712 DOI: 10.3389/fendo.2019.00242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
127 Christensen RM, Juhl CR, Torekov SS. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. Drug Saf 2019;42:957-71. [DOI: 10.1007/s40264-019-00812-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
128 Yehya A, Sadhu AR. New Therapeutic Strategies for Type 2 Diabetes CME. Methodist Debakey Cardiovasc J 2018;14:281-8. [PMID: 30788014 DOI: 10.14797/mdcj-14-4-281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
129 Oh TJ. The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. J Obes Metab Syndr 2019;28:158-66. [PMID: 31583380 DOI: 10.7570/jomes.2019.28.3.158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
130 Pal S, Maurya SK, Chattopadhyay S, Pal China S, Porwal K, Kulkarni C, Sanyal S, Sinha RA, Chattopadhyay N. The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts. Biochem Pharmacol 2019;164:34-44. [PMID: 30885766 DOI: 10.1016/j.bcp.2019.03.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
131 Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. Endocr Rev 2018;39:719-38. [PMID: 29905825 DOI: 10.1210/er.2018-00117] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 26.3] [Reference Citation Analysis]
132 Ji Y, Ge Y, Xu X, Ye S, Fan Y, Zhang J, Mei L, Zhang X, Ying L, Yang T, Li C. Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-κB Pathway. Front Pharmacol 2019;10:142. [PMID: 30858802 DOI: 10.3389/fphar.2019.00142] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
133 Gargallo-vaamonde J, Frühbeck G, Salvador J. New advances and novel approaches in obesity pharmacotherapy. Current Opinion in Endocrine and Metabolic Research 2019;4:75-82. [DOI: 10.1016/j.coemr.2018.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord 2019;19:4. [PMID: 30616638 DOI: 10.1186/s12902-018-0332-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
135 Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand 2019;139:26-36. [PMID: 30374965 DOI: 10.1111/acps.12982] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
136 Neuroendocrine Regulation of Appetite and Body Weight. Clinical Neuroendocrinology 2018. [DOI: 10.1017/9781108149938.005] [Reference Citation Analysis]
137 Roh JH, Yoon J. Bile Acids and the Metabolic Disorders. Korean J Clin Pharm 2018;28:273-278. [DOI: 10.24304/kjcp.2018.28.4.273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Zhou J, Poudel A, Chandramani-Shivalingappa P, Xu B, Welchko R, Li L. Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway. Endocrine 2019;64:271-83. [PMID: 30535743 DOI: 10.1007/s12020-018-1826-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
139 Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, Cappola TP, Margulies KB, Drucker DJ. GLP-1 Receptor Expression Within the Human Heart. Endocrinology 2018;159:1570-84. [PMID: 29444223 DOI: 10.1210/en.2018-00004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 117] [Article Influence: 28.5] [Reference Citation Analysis]
140 Hirota Y, Matsuda T, Nakajima S, Takabe M, Hashimoto N, Nakamura T, Okada Y, Sakaguchi K, Ogawa W. Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance. Endocrine 2019;64:43-7. [PMID: 30406884 DOI: 10.1007/s12020-018-1808-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Hope DCD, Tan TMM, Bloom SR. No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. Front Endocrinol (Lausanne) 2018;9:442. [PMID: 30158899 DOI: 10.3389/fendo.2018.00442] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
142 Antonsen KK, Klausen MK, Brunchmann AS, le Dous N, Jensen ME, Miskowiak KW, Fisher PM, Thomsen GK, Rindom H, Fahmy TP, Vollstaedt-Klein S, Benveniste H, Volkow ND, Becker U, Ekstrøm C, Knudsen GM, Vilsbøll T, Fink-Jensen A. Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 2018;8:e019562. [PMID: 30012779 DOI: 10.1136/bmjopen-2017-019562] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
143 Zhao L, Chen Y, Xia F, Abudukerimu B, Zhang W, Guo Y, Wang N, Lu Y. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne). 2018;9:233. [PMID: 29867765 DOI: 10.3389/fendo.2018.00233] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 14.0] [Reference Citation Analysis]
144 Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, Yao YH, Ma CY, Zhu CG, Guo YL, Wu NQ, Sun J, Chen BX, Li JJ. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol 2018;17:48. [PMID: 29618348 DOI: 10.1186/s12933-018-0689-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
145 Decara J, Rivera P, Arrabal S, Vargas A, Serrano A, Pavón FJ, Dieguez C, Nogueiras R, Rodríguez de Fonseca F, Suárez J. Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats. Acta Physiol (Oxf) 2018;222:e13008. [PMID: 29193738 DOI: 10.1111/apha.13008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
146 Zhu E, Yang Y, Zhang J, Li Y, Li C, Chen L, Sun B. Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro. Oncotarget 2016;7:81077-89. [PMID: 27835589 DOI: 10.18632/oncotarget.13189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
147 Ionescu CA, Popescu I, Banacu M, Dimitriu M. Lifestyle Changes and Weight Loss: Effects in PCOS. Debatable Topics in PCOS Patients 2018. [DOI: 10.5772/intechopen.73298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Sever MJ, Ferjan S, Janez A. Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome. Debatable Topics in PCOS Patients 2018. [DOI: 10.5772/intechopen.70648] [Reference Citation Analysis]
149 Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 2018;130:173-82. [PMID: 29388462 DOI: 10.1080/00325481.2018.1435129] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 15.3] [Reference Citation Analysis]
150 Mcelroy SL, Mori N, Guerdjikova AI, Keck PE. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Medical Hypotheses 2018;111:90-3. [DOI: 10.1016/j.mehy.2017.12.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
151 Li Y, Du J, Zhu E, Zhang J, Han J, Zhao W, Sun B, Tian D. Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway. Mol Med Rep. 2018;17:4499-4507. [PMID: 29344656 DOI: 10.3892/mmr.2018.8438] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
152 Semla TP, Ruser C, Good CB, Yanovski SZ, Ames D, Copeland LA, Billington C, Ferguson UI, Aronne LJ, Wadden TA, Garvey WT, Apovian CM, Atkins D. Pharmacotherapy for Weight Management in the VHA. J Gen Intern Med 2017;32:70-3. [PMID: 28271432 DOI: 10.1007/s11606-016-3949-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
153 Anandhakrishnan A, Korbonits M. Glucagon-Like Peptide 1 and Human Obesity. Practical Guide to Obesity Medicine 2018. [DOI: 10.1016/b978-0-323-48559-3.00003-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Madsbad S, Holst JJ. Treatment with GLP-1 Receptor Agonists. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_20] [Reference Citation Analysis]
155 Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, Grarup N, Stancáková A, Chen Y, Varga TV, Yaghootkar H, Luan J, Zhao JH, Willems SM, Wessel J, Wang S, Maruthur N, Michailidou K, Pirie A, van der Lee SJ, Gillson C, Al Olama AA, Amouyel P, Arriola L, Arveiler D, Aviles-Olmos I, Balkau B, Barricarte A, Barroso I, Garcia SB, Bis JC, Blankenberg S, Boehnke M, Boeing H, Boerwinkle E, Borecki IB, Bork-Jensen J, Bowden S, Caldas C, Caslake M, Cupples LA, Cruchaga C, Czajkowski J, den Hoed M, Dunn JA, Earl HM, Ehret GB, Ferrannini E, Ferrieres J, Foltynie T, Ford I, Forouhi NG, Gianfagna F, Gonzalez C, Grioni S, Hiller L, Jansson JH, Jørgensen ME, Jukema JW, Kaaks R, Kee F, Kerrison ND, Key TJ, Kontto J, Kote-Jarai Z, Kraja AT, Kuulasmaa K, Kuusisto J, Linneberg A, Liu C, Marenne G, Mohlke KL, Morris AP, Muir K, Müller-Nurasyid M, Munroe PB, Navarro C, Nielsen SF, Nilsson PM, Nordestgaard BG, Packard CJ, Palli D, Panico S, Peloso GM, Perola M, Peters A, Poole CJ, Quirós JR, Rolandsson O, Sacerdote C, Salomaa V, Sánchez MJ, Sattar N, Sharp SJ, Sims R, Slimani N, Smith JA, Thompson DJ, Trompet S, Tumino R, van der A DL, van der Schouw YT, Virtamo J, Walker M, Walter K, Abraham JE, Amundadottir LT, Aponte JL, Butterworth AS, Dupuis J, Easton DF, Eeles RA, Erdmann J, Franks PW, Frayling TM, Hansen T, Howson JM, Jørgensen T, Kooner J, Laakso M, Langenberg C, McCarthy MI, Pankow JS, Pedersen O, Riboli E, Rotter JI, Saleheen D, Samani NJ, Schunkert H, Vollenweider P, O'Rahilly S, Deloukas P, Danesh J, Goodarzi MO, Kathiresan S, Meigs JB, Ehm MG, Wareham NJ, Waterworth DM; CVD50 consortium., GERAD_EC Consortium., Neurology Working Group of the Cohorts for Heart., Aging Research in Genomic Epidemiology (CHARGE)., Alzheimer’s Disease Genetics Consortium., Pancreatic Cancer Cohort Consortium., European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD)., EPIC-InterAct., CHARGE consortium., CHD Exome+ Consortium., CARDIOGRAM Exome Consortium. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci Transl Med 2016;8:341ra76. [PMID: 27252175 DOI: 10.1126/scitranslmed.aad3744] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 16.0] [Reference Citation Analysis]
156 Rives-lange C, Ait Boudaoud A, Czernichow S, Carette C. Les traitements médicamenteux de l’obésité. Acta Endosc 2017;47:304-309. [DOI: 10.1007/s10190-017-0636-3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
157 Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, Mahendran Y, Iepsen EW, Finocchietto P, Jonsson AE, Madsbad S, Holst JJ, Vestergaard H, Hansen T, Torekov SS. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes Sci Pract 2017;3:425-33. [PMID: 29259801 DOI: 10.1002/osp4.133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
158 Kahan S, Fujioka K. Obesity Pharmacotherapy in Patients With Type 2 Diabetes. Diabetes Spectr 2017;30:250-7. [PMID: 29151715 DOI: 10.2337/ds17-0044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
159 Ritzel RA. Adipositas und Prädiabetes. Diabetologe 2017;13:482-486. [DOI: 10.1007/s11428-017-0274-y] [Reference Citation Analysis]
160 Gadde KM, Apolzan JW, Berthoud HR. Pharmacotherapy for Patients with Obesity. Clin Chem 2018;64:118-29. [PMID: 29054924 DOI: 10.1373/clinchem.2017.272815] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
161 Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes? Diabetes Metab Syndr Obes 2017;10:413-7. [PMID: 29042804 DOI: 10.2147/DMSO.S141571] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
162 Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet 2016;55:1413-22. [PMID: 27193270 DOI: 10.1007/s40262-016-0410-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
163 Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2017;74:719-28. [PMID: 28601891 DOI: 10.1001/jamapsychiatry.2017.1220] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 18.0] [Reference Citation Analysis]
164 Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102:709-57. [PMID: 28359099 DOI: 10.1210/jc.2016-2573] [Cited by in Crossref: 463] [Cited by in F6Publishing: 540] [Article Influence: 92.6] [Reference Citation Analysis]
165 Mancini MC, de Melo ME. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndr 2017;9:44. [PMID: 28580018 DOI: 10.1186/s13098-017-0242-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
166 Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017;19:1276-88. [PMID: 28345814 DOI: 10.1111/dom.12954] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
167 Wan Y, Bao X, Huang J, Zhang X, Liu W, Cui Q, Jiang D, Wang Z, Liu R, Wang Q. Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Front Physiol 2017;8:294. [PMID: 28555111 DOI: 10.3389/fphys.2017.00294] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
168 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;5:CD012204. [PMID: 28489279 DOI: 10.1002/14651858.CD012204.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
169 Li Z, Liang Y, Xia N, Lai Y, Pan H, Zhou S, Jiang F, He Y. Liraglutide reduces body weight by upregulation of adenylate cyclase 3. Nutr Diabetes 2017;7:e265. [PMID: 28481334 DOI: 10.1038/nutd.2017.17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
170 Kaineder K, Birngruber T, Rauter G, Obermüller B, Eichler J, Münzker J, Al-Zoughbi W, Mautner SI, Torekov SS, Hartmann B, Kotzbeck P, Pieber TR. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system. Int J Obes (Lond) 2017;41:1263-70. [PMID: 28507313 DOI: 10.1038/ijo.2017.98] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
171 le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399-409. [PMID: 28237263 DOI: 10.1016/S0140-6736(17)30069-7] [Cited by in Crossref: 359] [Cited by in F6Publishing: 364] [Article Influence: 71.8] [Reference Citation Analysis]
172 Kirk SF, Shamliyan TA, Middleton M. Glucagon-like peptide-1 agonists for weight loss in people with obesity. Obesity Medicine 2017;5:29-43. [DOI: 10.1016/j.obmed.2017.01.003] [Reference Citation Analysis]
173 Lam BYH, Cimino I, Polex-Wolf J, Nicole Kohnke S, Rimmington D, Iyemere V, Heeley N, Cossetti C, Schulte R, Saraiva LR, Logan DW, Blouet C, O'Rahilly S, Coll AP, Yeo GSH. Heterogeneity of hypothalamic pro-opiomelanocortin-expressing neurons revealed by single-cell RNA sequencing. Mol Metab 2017;6:383-92. [PMID: 28462073 DOI: 10.1016/j.molmet.2017.02.007] [Cited by in Crossref: 106] [Cited by in F6Publishing: 108] [Article Influence: 21.2] [Reference Citation Analysis]
174 Janez A, Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloska 7, 1525 Ljubljana, Slovenia, Jensterle M. Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome. JDO 2017;4:1-3. [DOI: 10.15436/2376-0494.17.1246] [Reference Citation Analysis]
175 Sekar R, Wang L, Chow BK. Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides. Front Endocrinol (Lausanne) 2017;8:18. [PMID: 28223965 DOI: 10.3389/fendo.2017.00018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
176 Hamann A. Adipositas: Gibt es sinnvolle medikamentöse Therapieansätze? Gynäkologe 2017;50:99-104. [DOI: 10.1007/s00129-016-4018-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
177 Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 2017;17:5. [PMID: 28143456 DOI: 10.1186/s12902-017-0155-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
178 Lam BYH, Cimino I, Polex-wolf J, Kohnke SN, Rimmington D, Iyemere V, Heeley N, Cossetti C, Schulte R, Saraiva LR, Logan DW, Blouet C, O’rahilly S, Coll AP, Yeo GSH. Heterogeneity of hypothalamic Pro-opiomelanocortin-expressing neurons revealed by single-cell RNA sequencing.. [DOI: 10.1101/103408] [Reference Citation Analysis]
179 Acosta A, Camilleri M. A working paradigm for the treatment of obesity in gastrointestinal practice. Tech Gastrointest Endosc 2017;19:52-60. [PMID: 28936110 DOI: 10.1016/j.tgie.2017.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
180 Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism 2017;70:192-5. [PMID: 28095990 DOI: 10.1016/j.metabol.2016.12.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
181 Elbelt U, Berger H, Hofmann T. Konservative Therapie der Adipositas. Adipositas- und metabolische Chirurgie 2017. [DOI: 10.1007/978-3-662-48698-6_2] [Reference Citation Analysis]
182 Iijima H, Kamei M. Longitudinal Evaluation and Meta-analysis of Clinical Articles on the Antihypertensive Effects of Incretin-related Drugs. Jpn J Pharm Health Care Sci 2017;43:201-214. [DOI: 10.5649/jjphcs.43.201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Camilleri M, Abu Dayyeh B, Acosta A. The Management of Obesity. Metabolism and Pathophysiology of Bariatric Surgery 2017. [DOI: 10.1016/b978-0-12-804011-9.00003-0] [Reference Citation Analysis]
184 Leskova I, Ermakov D, Matushevskaya E, Nishnianidze O. Socio-medical aspects of the normalization of body mass. Obes metabol 2016;13:49-52. [DOI: 10.14341/omet2016449-52] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
185 Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3:3-14. [PMID: 28392927 DOI: 10.1002/osp4.84] [Cited by in Crossref: 106] [Cited by in F6Publishing: 116] [Article Influence: 17.7] [Reference Citation Analysis]
186 Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 [PMID: 28031776 DOI: 10.4239/wjd.v7.i20.572] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
187 Schultes B. Pharmacological Interventions against Obesity: Current Status and Future Directions. Visc Med 2016;32:347-51. [PMID: 27921047 DOI: 10.1159/000450904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 2016;15:162. [PMID: 27912784 DOI: 10.1186/s12933-016-0480-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 12.8] [Reference Citation Analysis]
189 Advances in Pharmacological Treatment of Pediatric Obesity. Childhood Obesity 2016. [DOI: 10.1201/9781315370958-31] [Reference Citation Analysis]
190 Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab 2017;19:49-60. [PMID: 27550386 DOI: 10.1111/dom.12779] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
191 Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep. 2016;6:33251. [PMID: 27633081 DOI: 10.1038/srep33251] [Cited by in Crossref: 81] [Cited by in F6Publishing: 85] [Article Influence: 13.5] [Reference Citation Analysis]
192 Arch JR. Horizons in the Pharmacotherapy of Obesity. Curr Obes Rep 2015;4:451-9. [PMID: 26346394 DOI: 10.1007/s13679-015-0177-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
193 Millar K, Poole R. Current drugs for weight loss. Pract Diab 2016;33:229-232. [DOI: 10.1002/pdi.2044] [Reference Citation Analysis]
194 Van Gaal L, Dirinck E. Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. Diabetes Care 2016;39 Suppl 2:S260-7. [PMID: 27440841 DOI: 10.2337/dcS15-3016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
195 Sarraju A, Kim SH, Knowles JW. Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. Curr Atheroscler Rep 2016;18:7. [PMID: 26782825 DOI: 10.1007/s11883-016-0558-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
196 Kabade DM, Koppad A, Khatawkar A, Kabade SD, Ahmed A. ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS. jebmh 2016;3:2272-2282. [DOI: 10.18410/jebmh/2016/503] [Reference Citation Analysis]
197 Abramowitz MK, Sharma D, Folkert VW. Hidden Obesity in Dialysis Patients: Clinical Implications. Semin Dial 2016;29:391-5. [PMID: 27144783 DOI: 10.1111/sdi.12516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
198 López-lópez J, Di Stefano KA, Velásquez E, Camacho PA, López-jaramillo P. ¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica? Revista Colombiana de Cardiología 2016;23:200-9. [DOI: 10.1016/j.rccar.2015.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
199 Lahiri SW. Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed? Clin Diabetes 2016;34:115-20. [PMID: 27092024 DOI: 10.2337/diaclin.34.2.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
200 Hodge RJ, Paulik MA, Walker A, Boucheron JA, McMullen SL, Gillmor DS, Nunez DJ. Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes. PLoS One 2016;11:e0153151. [PMID: 27093610 DOI: 10.1371/journal.pone.0153151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
201 Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10:407-413. [PMID: 27069358 DOI: 10.2147/ppa.s97383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
202 Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016;40:1310-9. [PMID: 27005405 DOI: 10.1038/ijo.2016.52] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 28.2] [Reference Citation Analysis]
203 Giordano A, Frontini A, Cinti S. Convertible visceral fat as a therapeutic target to curb obesity. Nat Rev Drug Discov 2016;15:405-24. [PMID: 26965204 DOI: 10.1038/nrd.2016.31] [Cited by in Crossref: 146] [Cited by in F6Publishing: 147] [Article Influence: 24.3] [Reference Citation Analysis]
204 Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab 2016;18:491-9. [PMID: 26833744 DOI: 10.1111/dom.12639] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
205 Xu F, Lin B, Zheng X, Chen Z, Cao H, Xu H, Liang H, Weng J. GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia. 2016;59:1059-1069. [PMID: 26924394 DOI: 10.1007/s00125-016-3896-5] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
206 Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371. [PMID: 26998259 DOI: 10.1177/2048004016633371] [Cited by in Crossref: 176] [Cited by in F6Publishing: 213] [Article Influence: 29.3] [Reference Citation Analysis]
207 Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. Exp Ther Med 2016;11:1194-200. [PMID: 27073422 DOI: 10.3892/etm.2016.3081] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
208 Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75:899-910. [PMID: 25985864 DOI: 10.1007/s40265-015-0408-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
209 Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-108. [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001] [Cited by in Crossref: 275] [Cited by in F6Publishing: 239] [Article Influence: 45.8] [Reference Citation Analysis]
210 Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep 2015;17:35. [PMID: 25894803 DOI: 10.1007/s11886-015-0590-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
211 Verma A, Verma D. TREATMENT OF OBESITY: NEWER PERSPECTIVES. jemds 2016;5:112-113. [DOI: 10.14260/jemds/2016/27] [Reference Citation Analysis]
212 Drucker DJ. Glucagon and the Glucagon-Like Peptides. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00034-2] [Reference Citation Analysis]
213 Clarke R, Bloom S, Tan T. Gut Hormones. Encyclopedia of Food and Health 2016. [DOI: 10.1016/b978-0-12-384947-2.00366-4] [Reference Citation Analysis]
214 Blackstone RP. Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. Obesity 2016. [DOI: 10.1007/978-3-319-39409-1_10] [Reference Citation Analysis]
215 Curtis L, Holt H, Richardson T, Knott J, Partridge H. GLP-1 analogue use in patients with sub-optimally controlled type 1 diabetes or obesity improves weight and HbA1c. Pract Diab 2016;33:13-17. [DOI: 10.1002/pdi.1991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
216 Klein S, Romijn JA. Obesity. Williams Textbook of Endocrinology 2016. [DOI: 10.1016/b978-0-323-29738-7.00036-8] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
217 Ahima RS. Pharmacotherapy of Obesity and Metabolic Syndrome. Metabolic Syndrome 2016. [DOI: 10.1007/978-3-319-11251-0_44] [Reference Citation Analysis]
218 Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis 2016;7:92-107. [PMID: 26977279 DOI: 10.1177/2040622315620180] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
219 Kumar N, Choudhary NS. Treating morbid obesity in cirrhosis: A quest of holy grail. World J Hepatol 2015; 7(28): 2819-2828 [PMID: 26668693 DOI: 10.4254/wjh.v7.i28.2819] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
220 Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts 2015;8:402-24. [PMID: 26641646 DOI: 10.1159/000442721] [Cited by in Crossref: 565] [Cited by in F6Publishing: 604] [Article Influence: 80.7] [Reference Citation Analysis]
221 Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes 2015; 6(15): 1285-1295 [PMID: 26557956 DOI: 10.4239/wjd.v6.i15.1285] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
222 De Jonghe BC, Holland RA, Olivos DR, Rupprecht LE, Kanoski SE, Hayes MR. Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. Physiol Behav 2016;153:109-14. [PMID: 26522737 DOI: 10.1016/j.physbeh.2015.10.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
223 Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol Med 2015;7:288-98. [PMID: 25652173 DOI: 10.15252/emmm.201404508] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
224 Liu AY, Silvestre MP, Poppitt SD. Prevention of type 2 diabetes through lifestyle modification: is there a role for higher-protein diets? Adv Nutr 2015;6:665-73. [PMID: 26567192 DOI: 10.3945/an.115.008821] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
225 Soleymani T, Daniel S, Garvey WT. Weight maintenance: challenges, tools and strategies for primary care physicians. Obes Rev 2016;17:81-93. [PMID: 26490059 DOI: 10.1111/obr.12322] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
226 Liu L, Segura A, Hagemann AR. Obesity Education Strategies for Cancer Prevention in Women's Health. Curr Obstet Gynecol Rep 2015;4:249-58. [PMID: 26877893 DOI: 10.1007/s13669-015-0129-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
227 Scott LJ. Liraglutide in obesity: a guide to its use in the EU. Drugs Ther Perspect 2015;31:334-340. [DOI: 10.1007/s40267-015-0241-x] [Reference Citation Analysis]
228 Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 [PMID: 26464759 DOI: 10.4239/wjd.v6.i12.1207] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
229 Mujeeb MMA, Divhare SA. ANTI - OBESITY DRUGS : PRESENT AND FUTURE. jemds 2015;4:13489-500. [DOI: 10.14260/jemds/2015/1931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM. Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients. Clin Med Insights Endocrinol Diabetes 2015;8:67-72. [PMID: 26441485 DOI: 10.4137/CMED.S31756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
231 ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, IJzerman RG. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 2015;58:2688-98. [PMID: 26385462 DOI: 10.1007/s00125-015-3754-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
232 Siegmund T. Hochdosiertes GLP-1-Analogon zur Gewichtskontrolle erfolgreich. Info Diabetol 2015;9:27-28. [DOI: 10.1007/s15034-015-0632-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Gilmartin J, Murphy M. The effects of contemporary behavioural weight loss maintenance interventions for long term weight loss: a systematic review. Journal of Research in Nursing 2015;20:481-496. [DOI: 10.1177/1744987115599671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
234 Turer CB. Tools for Successful Weight Management in Primary Care. Am J Med Sci 2015;350:485-97. [PMID: 26218666 DOI: 10.1097/MAJ.0000000000000530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
235 Palikhe G, Gupta R, Behera BN, Sachdeva N, Gangadhar P, Bhansali A. Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus. Obes Surg 2014;24:529-35. [PMID: 24272885 DOI: 10.1007/s11695-013-1114-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
236 Busetto L, Dixon J, De Luca M, Shikora S, Pories W, Angrisani L. Bariatric surgery in class I obesity: a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2014;24:487-519. [PMID: 24638958 DOI: 10.1007/s11695-014-1214-1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
237 Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One 2015;10:e0132744. [PMID: 26177280 DOI: 10.1371/journal.pone.0132744] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
238 Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. [PMID: 26213556 DOI: 10.7573/dic.212283] [Cited by in Crossref: 197] [Cited by in F6Publishing: 212] [Article Influence: 28.1] [Reference Citation Analysis]
239 Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015;98:145-61. [PMID: 25963811 DOI: 10.1002/cpt.143] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
240 Sheridan S. A review of a self-prescribed medication regime in undiagnosed diabetes. Journal of Paramedic Practice 2015;7:350-354. [DOI: 10.12968/jpar.2015.7.7.350] [Reference Citation Analysis]
241 Aroda VR, Getaneh A. Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab 2015;10:381-98. [PMID: 30293496 DOI: 10.1586/17446651.2015.1054280] [Reference Citation Analysis]
242 Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLoS One 2015;10:e0126769. [PMID: 26121478 DOI: 10.1371/journal.pone.0126769] [Cited by in Crossref: 107] [Cited by in F6Publishing: 115] [Article Influence: 15.3] [Reference Citation Analysis]
243 Gautron L, Elmquist JK, Williams KW. Neural control of energy balance: translating circuits to therapies. Cell 2015;161:133-45. [PMID: 25815991 DOI: 10.1016/j.cell.2015.02.023] [Cited by in Crossref: 163] [Cited by in F6Publishing: 171] [Article Influence: 23.3] [Reference Citation Analysis]
244 Hoang V, Bi J, Mohankumar SM, Vyas AK. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS One 2015;10:e0126119. [PMID: 26010091 DOI: 10.1371/journal.pone.0126119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
245 MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes 2015;8:241-53. [PMID: 26056482 DOI: 10.2147/DMSO.S77290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
246 Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015;23:1119-1129. [PMID: 25959380 DOI: 10.1002/oby.21107] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
247 Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39:1188-1196. [PMID: 25896063 DOI: 10.1038/ijo.2015.59] [Cited by in Crossref: 213] [Cited by in F6Publishing: 221] [Article Influence: 30.4] [Reference Citation Analysis]
248 Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord 2015;15:14. [PMID: 25880805 DOI: 10.1186/s12902-015-0005-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
249 López M, Diéguez C, Nogueiras R. Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat. Adipocyte 2015;4:141-5. [PMID: 26167417 DOI: 10.4161/21623945.2014.983752] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
250 Kim KK. Safety of Anti-Obesity Drugs Approved for Long-Term Use. Korean J Obes 2015;24:17-27. [DOI: 10.7570/kjo.2015.24.1.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
251 Hakon J, Ruscher K, Romner B, Tomasevic G. Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PLoS One 2015;10:e0120074. [PMID: 25822252 DOI: 10.1371/journal.pone.0120074] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
252 Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15:181-7. [PMID: 24811133 DOI: 10.1007/s11154-014-9289-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 16.3] [Reference Citation Analysis]
253 Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci. 2015;9:92. [PMID: 25852463 DOI: 10.3389/fnins.2015.00092] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
254 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 242] [Cited by in F6Publishing: 256] [Article Influence: 34.6] [Reference Citation Analysis]
255 Astrup A. Treatment of obesity: lifestyle and pharmacotherapy. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch33] [Reference Citation Analysis]
256 Yates T, Davies MJ. Prevention of type 2 diabetes. International Textbook of Diabetes Mellitus 2015. [DOI: 10.1002/9781118387658.ch38] [Reference Citation Analysis]
257 Schumacher D. Pharmacological Management of the Obese Patient. American Journal of Lifestyle Medicine 2015;9:137-156. [DOI: 10.1177/1559827613504733] [Reference Citation Analysis]
258 Myat A, Arri S, Bhatt DL, Gersh BJ, Redwood SR, Marber MS. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study. Cardiovasc Diabetol 2015;14:27. [PMID: 25848859 DOI: 10.1186/s12933-015-0193-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
259 Yu YH, Vasselli JR, Zhang Y, Mechanick JI, Korner J, Peterli R. Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications. Obes Rev 2015;16:234-47. [PMID: 25588316 DOI: 10.1111/obr.12246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
260 Kanoski SE, Ong ZY, Fortin SM, Schlessinger ES, Grill HJ. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms. Diabetes Obes Metab 2015;17:285-93. [PMID: 25475828 DOI: 10.1111/dom.12423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
261 Benkert O. Medikamente zur Behandlung von Essstörungen und Adipositas. Kompendium der Psychiatrischen Pharmakotherapie 2015. [DOI: 10.1007/978-3-642-54769-0_9] [Reference Citation Analysis]
262 Ahima RS. Pharmacotherapy of Obesity and Metabolic Syndrome. Metabolic Syndrome 2015. [DOI: 10.1007/978-3-319-12125-3_44-1] [Reference Citation Analysis]
263 Sumithran P, Proietto J. Very-low-calorie diets (VLCDs) for the treatment of obesity. Managing and Preventing Obesity 2015. [DOI: 10.1533/9781782420996.4.231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
264 Bray GA, Ryan DH. The Doctor’s Tool Kit: Pharmacotherapy for the Patient with Obesity. The Clinician’s Guide to the Treatment of Obesity 2015. [DOI: 10.1007/978-1-4939-2146-1_6] [Reference Citation Analysis]
265 Burguera B, Tur J. 3 Medical Management of Obesity. Minimally Invasive Bariatric Surgery 2015. [DOI: 10.1007/978-1-4939-1637-5_3] [Reference Citation Analysis]
266 Preiato VL, Serban ED, Pasquali R, Pagotto U. Prescription Medications for the Treatment of Obesity. Multidisciplinary Approach to Obesity 2015. [DOI: 10.1007/978-3-319-09045-0_23] [Reference Citation Analysis]
267 Grunberger G, Garber AJ, Mechanick JI. Obesity management: applying clinical trial data to clinical care. Endocr Pract 2014;20 Suppl 2:6-19. [PMID: 25526732 DOI: 10.4158/EP14490.RA] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
268 References. Off-label prescribing - Justifying unapproved medicine 2014. [DOI: 10.1002/9781118912065.bref] [Reference Citation Analysis]
269 Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834 [PMID: 25512784 DOI: 10.4239/wjd.v5.i6.817] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
270 . Correction to: Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opin Pharmacother 2015;16:147. [PMID: 25490726 DOI: 10.1517/14656566.2015.995863] [Reference Citation Analysis]
271 Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 2015;172:721-36. [PMID: 25231355 DOI: 10.1111/bph.12943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
272 Rubio MA. Pharmacological treatment of obesity in Europe: Waiting for the arrival of the white blackbird. Endocrinología y Nutrición (English Edition) 2014;61:501-504. [DOI: 10.1016/j.endoen.2014.11.001] [Reference Citation Analysis]
273 Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T, Wakabayashi G. Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164. [PMID: 25386164 DOI: 10.3389/fendo.2014.00164] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
274 Iepsen EW, Lundgren J, Dirksen C, Jensen JE, Pedersen O, Hansen T, Madsbad S, Holst JJ, Torekov SS. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond) 2015;39:834-41. [PMID: 25287751 DOI: 10.1038/ijo.2014.177] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
275 Camilleri M. Peripheral mechanisms in appetite regulation. Gastroenterology. 2015;148:1219-1233. [PMID: 25241326 DOI: 10.1053/j.gastro.2014.09.016] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 15.9] [Reference Citation Analysis]
276 Scott RV, Tan TM, Bloom SR. Can Bayliss and Starling gut hormones cure a worldwide pandemic? J Physiol 2014;592:5153-67. [PMID: 25217372 DOI: 10.1113/jphysiol.2014.272955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
277 Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473-4488. [PMID: 25202980 DOI: 10.1172/jci75276] [Cited by in Crossref: 458] [Cited by in F6Publishing: 477] [Article Influence: 57.3] [Reference Citation Analysis]
278 Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne) 2014;5:140. [PMID: 25221543 DOI: 10.3389/fendo.2014.00140] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
279 Tan TM, Salem V, Troke RC, Alsafi A, Field BC, De Silva A, Misra S, Baynes KC, Donaldson M, Minnion J, Ghatei MA, Godsland IF, Bloom SR. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. J Clin Endocrinol Metab 2014;99:E2317-24. [PMID: 25144632 DOI: 10.1210/jc.2014-2143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
280 . The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised). Journal of Endocrinology, Metabolism and Diabetes of South Africa 2014;17:S1-S95. [DOI: 10.1080/22201009.2012.10872287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
281 Cheung BM, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf 2013;4:171-81. [PMID: 25114779 DOI: 10.1177/2042098613489721] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 11.5] [Reference Citation Analysis]
282 Arabin B, Stupin JH. Overweight and Obesity before, during and after Pregnancy: Part 2: Evidence-based Risk Factors and Interventions. Geburtshilfe Frauenheilkd 2014;74:646-55. [PMID: 25100879 DOI: 10.1055/s-0034-1368462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
283 Stranges P, Khanderia U. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf 2012;3:185-201. [PMID: 25083236 DOI: 10.1177/2042098612454290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
284 Cummings BP, Graham JL, Stanhope KL, Chouinard ML, Havel PJ. Maternal ileal interposition surgery confers metabolic improvements to offspring independent of effects on maternal body weight in UCD-T2DM rats. Obes Surg 2013;23:2042-9. [PMID: 24036841 DOI: 10.1007/s11695-013-1076-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
285 Merlino DJ, Blomain ES, Aing AS, Waldman SA. Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. J Clin Med 2014;3:763-94. [PMID: 26237477 DOI: 10.3390/jcm3030763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
286 Li WX, Gou JF, Yan X, Yang L. Metformin for obesity or overweight. Cochrane Database of Systematic Reviews 2014. [DOI: 10.1002/14651858.cd008835.pub2] [Reference Citation Analysis]
287 Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014;5:135-48. [PMID: 24790728 DOI: 10.1177/2040622314522848] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 8.5] [Reference Citation Analysis]
288 Goswami G, Shinkazh N, Davis N. Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J Clin Med 2014;3:595-613. [PMID: 26237392 DOI: 10.3390/jcm3020595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
289 Kaku K, Rasmussen MF, Nishida T, Seino Y. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Investig 2011;2:441-7. [PMID: 24843528 DOI: 10.1111/j.2040-1124.2011.00128.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
290 Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S226-S232. [PMID: 23882050 DOI: 10.2337/dcs13-2036] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
291 Acosta A, Abu Dayyeh BK, Port JD, Camilleri M. Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 2014;63:687-95. [PMID: 24402654 DOI: 10.1136/gutjnl-2013-306235] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 8.8] [Reference Citation Analysis]
292 Alhadeff AL, Baird JP, Swick JC, Hayes MR, Grill HJ. Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology 2014;39:2233-43. [PMID: 24681814 DOI: 10.1038/npp.2014.74] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 10.4] [Reference Citation Analysis]
293 Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjær A, Correll CU, Vilsbøll T, Fink-Jensen A. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 2014;4:e004227. [PMID: 24667381 DOI: 10.1136/bmjopen-2013-004227] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
294 Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag 2014;10:173-88. [PMID: 24672242 DOI: 10.2147/TCRM.S39564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis]
295 Ulrich-Lai YM, Ryan KK. Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications. Cell Metab. 2014;19:910-925. [PMID: 24630812 DOI: 10.1016/j.cmet.2014.01.020] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 8.5] [Reference Citation Analysis]
296 Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine 2014;47:360-71. [PMID: 24604239 DOI: 10.1007/s12020-014-0223-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
297 Femminella GD, Edison P. The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimer’s disease. Clinical Investigation 2014;4:201-203. [DOI: 10.4155/cli.14.12] [Reference Citation Analysis]
298 Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013;19:536-557. [PMID: 23816937 DOI: 10.4158/ep13176.cs] [Cited by in Crossref: 148] [Cited by in F6Publishing: 193] [Article Influence: 18.5] [Reference Citation Analysis]
299 Kalra S. Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach. Diabetes Ther 2014;5:333-40. [PMID: 24549850 DOI: 10.1007/s13300-014-0058-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
300 Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451-459. [PMID: 24362411 DOI: 10.1530/eje-13-0797] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
301 Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, Yu DM. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol 2014;13:36. [PMID: 24498905 DOI: 10.1186/1475-2840-13-36] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
302 Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsbøll T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 2014;51:147-50. [PMID: 22160246 DOI: 10.1007/s00592-011-0359-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
303 Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 2013;13:307-18. [PMID: 23479200 DOI: 10.1007/s11892-013-0377-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
304 Hankir A, Hankir M, Zaman R. Should Ramadan be prescribed after Christmas? Obesity in the healthcare profession and the health benefits of fasting. BMJ Case Rep 2014;2014:bcr2013202704. [PMID: 24429052 DOI: 10.1136/bcr-2013-202704] [Reference Citation Analysis]
305 Valentino MA, Colon-Gonzalez F, Lin JE, Waldman SA. Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Rev Endocrinol Metab 2010;5:765-83. [PMID: 21297878 DOI: 10.1586/eem.10.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
306 Crujeiras AB, Díaz-Lagares A, Abete I, Goyenechea E, Amil M, Martínez JA, Casanueva FF. Pre-treatment circulating leptin/ghrelin ratio as a non-invasive marker to identify patients likely to regain the lost weight after an energy restriction treatment. J Endocrinol Invest 2014;37:119-26. [PMID: 24497210 DOI: 10.1007/s40618-013-0004-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
307 Logue J, Allardice G, Gillies M, Forde L, Morrison DS. Outcomes of a specialist weight management programme in the UK National Health Service: prospective study of 1838 patients. BMJ Open 2014;4:e003747. [PMID: 24394799 DOI: 10.1136/bmjopen-2013-003747] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
308 Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, Rajagopalan S. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014;27:130-9. [PMID: 24263424 DOI: 10.1093/ajh/hpt196] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 10.8] [Reference Citation Analysis]
309 Ueno H, Nakazato M. The Prospects of Novel Anti-obesity Drugs. J Jpn Soc Intern Med 2014;103:753-759. [DOI: 10.2169/naika.103.753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
310 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-2311-3_16] [Reference Citation Analysis]
311 Powell AG, Apovian C. Pharmacotherapy Management of Obesity. The ASMBS Textbook of Bariatric Surgery 2014. [DOI: 10.1007/978-1-4939-1197-4_16] [Reference Citation Analysis]
312 Fujishima Y, Maeda N. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Visceral Fat Adiposity, Appetite, and Food Preference. Nutrition in the Prevention and Treatment of Abdominal Obesity 2014. [DOI: 10.1016/b978-0-12-407869-7.00015-5] [Reference Citation Analysis]
313 Ammon HPT, Burchard A, Drexel H, Füchtenbusch M, Häring H, Hauner H, Joost H, Matthaei S, Merkel M, Müller-wieland D, Pfohl M, Roden M, Rustenbeck I, Säly C, Schatz H, Schifferdecker E, Schinner S, Schwarz P, Szendrödi J, Vonbank A, Wascher T, Zeyfang A. Typ-2-Diabetes. Diabetologie kompakt 2014. [DOI: 10.1007/978-3-642-41358-2_4] [Reference Citation Analysis]
314 Dicembrini I, Bigiarini M, Mannucci E. Lixisenatide: clinical profile and available evidence. Diabetes Management 2014;4:71-84. [DOI: 10.2217/dmt.13.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
315 Pasarica M, Smith SR. Drugs for Weight Loss and Maintenance: Present and Future. Treatment of the Obese Patient 2014. [DOI: 10.1007/978-1-4939-1203-2_16] [Reference Citation Analysis]
316 Cerezo C, Segura J, Praga M, Ruilope LM. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. Curr Hypertens Rep 2013;15:196-203. [PMID: 23519746 DOI: 10.1007/s11906-013-0337-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
317 Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103. [PMID: 24375052 DOI: 10.1038/nrneph.2013.272] [Cited by in Crossref: 131] [Cited by in F6Publishing: 137] [Article Influence: 14.6] [Reference Citation Analysis]
318 Chen H, Simar D, Pegg K, Saad S, Palmer C, Morris MJ. Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents. Diabetologia. 2014;57:614-622. [PMID: 24337156 DOI: 10.1007/s00125-013-3132-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
319 Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Reaven G. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia. 2014;57:455-462. [PMID: 24326527 DOI: 10.1007/s00125-013-3134-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
320 Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. [PMID: 24189085 DOI: 10.1136/bmjopen-2013-003995] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
321 Foghsgaard S, Vedtofte L, Mathiesen ER, Svare JA, Gluud LL, Holst JJ, Damm P, Knop FK, Vilsbøll T. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open 2013;3:e003834. [PMID: 24176797 DOI: 10.1136/bmjopen-2013-003834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
322 Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013;7:181. [PMID: 24133407 DOI: 10.3389/fnins.2013.00181] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 11.1] [Reference Citation Analysis]
323 Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel) 2013;6:1304-21. [PMID: 24275851 DOI: 10.3390/ph6101304] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
324 Mietlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, Pierce RC, Hayes MR. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 2013;305:E1367-74. [PMID: 24105414 DOI: 10.1152/ajpendo.00413.2013] [Cited by in Crossref: 108] [Cited by in F6Publishing: 121] [Article Influence: 12.0] [Reference Citation Analysis]
325 Ransom T, Goldenberg R, Mikalachki A, Prebtani AP, Punthakee Z. Réduction du risque de diabète. Canadian Journal of Diabetes 2013;37:S377-S380. [DOI: 10.1016/j.jcjd.2013.07.033] [Reference Citation Analysis]
326 Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev 2013;9:33-54. [PMID: 23092275 DOI: 10.2174/157340313805076322] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
327 Page KA, Reisman T. Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes. Curr Diab Rep 2013;13:252-60. [PMID: 23371283 DOI: 10.1007/s11892-013-0363-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
328 van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784-793. [PMID: 23999198 DOI: 10.1038/ijo.2013.162] [Cited by in Crossref: 257] [Cited by in F6Publishing: 269] [Article Influence: 28.6] [Reference Citation Analysis]
329 Khavandi K, Amer H, Ibrahim B, Brownrigg J. Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis. 2013;4:242-261. [PMID: 23997928 DOI: 10.1177/2040622313494986] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
330 Simon M, Roden M, Müssig K. Inkretine. Diabetologe 2013;9:463-466. [DOI: 10.1007/s11428-013-1058-7] [Reference Citation Analysis]
331 Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A; NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:689-97. [PMID: 23942319 DOI: 10.1038/ijo.2013.149] [Cited by in Crossref: 112] [Cited by in F6Publishing: 118] [Article Influence: 12.4] [Reference Citation Analysis]
332 Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, Grove K, Tomasso V, Ochoa H, Liu YV. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36:3276-3282. [PMID: 23835684 DOI: 10.2337/dc13-0354] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 6.6] [Reference Citation Analysis]
333 Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167:355-360. [PMID: 23380890 DOI: 10.1001/jamapediatrics.2013.1045] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 12.3] [Reference Citation Analysis]
334 Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh. Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs. J Pharm Nutr Sci 2013;3:178-190. [DOI: 10.6000/1927-5951.2013.03.03.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
335 Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications 2013;27:508-18. [PMID: 23726071 DOI: 10.1016/j.jdiacomp.2013.04.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
336 Mul JD, Begg DP, Barrera JG, Li B, Matter EK, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. Am J Physiol Regul Integr Comp Physiol 2013;305:R68-77. [PMID: 23616105 DOI: 10.1152/ajpregu.00588.2012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
337 Pharmacotherapy. Practical Manual of Clinical Obesity 2013. [DOI: 10.1002/9781118643570.ch11] [Reference Citation Analysis]
338 Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2013;9:425-433. [PMID: 23478327 DOI: 10.1038/nrendo.2013.47] [Cited by in Crossref: 143] [Cited by in F6Publishing: 144] [Article Influence: 15.9] [Reference Citation Analysis]
339 Roe ED, Pon NC, Hollander P, Raskin P. The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes. Diabetes Management 2013;3:145-160. [DOI: 10.2217/dmt.13.5] [Reference Citation Analysis]
340 Neff KJ, Roux CWL. Incretins: new targets for the prevention of diabetes and obesity. Clinical Lipidology 2013;8:109-121. [DOI: 10.2217/clp.12.80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
341 Carter R, Mouralidarane A, Ray S, Soeda J, Oben J. Recent advancements in drug treatment of obesity. Clin Med (Lond) 2012;12:456-60. [PMID: 23101148 DOI: 10.7861/clinmedicine.12-5-456] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
342 Moroshko I, Brennan L, O'Brien P. Predictors of attrition in bariatric aftercare: a systematic review of the literature. Obes Surg 2012;22:1640-7. [PMID: 22696275 DOI: 10.1007/s11695-012-0691-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 9.8] [Reference Citation Analysis]
343 Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013;37:1161-1168. [PMID: 23295502 DOI: 10.1038/ijo.2012.208] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 12.0] [Reference Citation Analysis]
344 Harcourt BE, Penfold SA, Forbes JM. Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol 2013;9:113-23. [PMID: 23296171 DOI: 10.1038/nrendo.2012.236] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
345 Rodgers RJ, Tschöp MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012;5:621-6. [PMID: 22915024 DOI: 10.1242/dmm.009621] [Cited by in Crossref: 302] [Cited by in F6Publishing: 311] [Article Influence: 33.6] [Reference Citation Analysis]
346 Poppitt S. Carbohydrates and satiety *. Satiation, Satiety and the Control of Food Intake 2013. [DOI: 10.1533/9780857098719.3.166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
347 Hauner H, Wirth A, Gola U, Teufel M, Zipfel S, de Zwaan M, Hüttl T, Kramer K, Winckler K. Management und Therapie. Adipositas 2013. [DOI: 10.1007/978-3-642-22855-1_7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
348 Field BC. What's new in…..obesity. Neuroendocrinology of obesity and the potential for new treatments. Medicine 2013;41:53-57. [DOI: 10.1016/j.mpmed.2012.10.003] [Reference Citation Analysis]
349 Benkert O, Hippius H. Medikamente zur Behandlung von Essstörungen und Adipositas. Kompendium der Psychiatrischen Pharmakotherapie 2013. [DOI: 10.1007/978-3-642-29810-3_9] [Reference Citation Analysis]
350 Svačina Š. Treatment of Obese Diabetics. Advances in Experimental Medicine and Biology 2013. [DOI: 10.1007/978-1-4614-5441-0_32] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
351 Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62:1131-1138. [PMID: 23248172 DOI: 10.2337/db12-0797] [Cited by in Crossref: 150] [Cited by in F6Publishing: 152] [Article Influence: 15.0] [Reference Citation Analysis]
352 Jindal A, Brietzke S, Sowers JR. Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. Cardiorenal Med 2012;2:314-27. [PMID: 23380694 DOI: 10.1159/000343803] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
353 Baynes KC. The evolving world of GLP-1 agonist therapies for type 2 diabetes. Ther Adv Endocrinol Metab 2010;1:61-7. [PMID: 23148151 DOI: 10.1177/2042018810375414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
354 Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15:485-502. [PMID: 23061470 DOI: 10.1111/dom.12025] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 10.3] [Reference Citation Analysis]
355 Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, Balena R. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498-504. [PMID: 23139373 DOI: 10.2337/dc12-0709] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
356 Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 2012;11:107. [PMID: 22973968 DOI: 10.1186/1475-2840-11-107] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
357 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-742. [PMID: 22945360 DOI: 10.1038/nrendo.2012.140] [Cited by in Crossref: 753] [Cited by in F6Publishing: 793] [Article Influence: 75.3] [Reference Citation Analysis]
358 Verma A. Non-diabetic use of liraglutide. Indian J Endocrinol Metab 2012;16:864-5. [PMID: 23087891 DOI: 10.4103/2230-8210.100698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
359 Gupta AK. Diabetes obesity link: how to lower your risk of diabetes with weight management. Osteopathic Family Physician 2012;4:149-154. [DOI: 10.1016/j.osfp.2012.05.001] [Reference Citation Analysis]
360 Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, Ananthakrishnan G, Rohner-Jeanrenaud F, Drucker DJ, DiMarchi R, Rahmouni K, Oldfield BJ, Tschöp MH, Perez-Tilve D. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012;61:2753-62. [PMID: 22933116 DOI: 10.2337/db11-1556] [Cited by in Crossref: 167] [Cited by in F6Publishing: 171] [Article Influence: 16.7] [Reference Citation Analysis]
361 Sherafat-Kazemzadeh R, Yanovski SZ, Yanovski JA. Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) 2013;37:1-15. [PMID: 22929210 DOI: 10.1038/ijo.2012.144] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
362 Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs 2011;71:2347-73. [PMID: 22085389 DOI: 10.2165/11208110-000000000-00000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
363 Di Pasquale G, Dicembrini I, Raimondi L, Pagano C, Egan JM, Cozzi A, Cinci L, Loreto A, Manni ME, Berretti S, Morelli A, Zheng C, Michael DG, Maggi M, Vettor R, Chiorini JA, Mannucci E, Rotella CM. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. PLoS One 2012;7:e40074. [PMID: 22808093 DOI: 10.1371/journal.pone.0040074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
364 Luque L, Riera A, Burguera B. Cirugía bariátrica y diabetes mellitus tipo 2. ¿Son todas las técnicas quirúrgicas iguales? Avances en Diabetología 2012;28:81-88. [DOI: 10.1016/j.avdiab.2012.09.002] [Reference Citation Analysis]
365 Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. [PMID: 22683128 DOI: 10.1016/s0140-6736(12)60283-9] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1478] [Article Influence: 138.8] [Reference Citation Analysis]
366 Rao G. A Role for Emerging Obesity Drugs. Curr Cardiovasc Risk Rep 2012;6:185-187. [DOI: 10.1007/s12170-012-0228-2] [Reference Citation Analysis]
367 Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012;49:225-30. [PMID: 21898126 DOI: 10.1007/s00592-011-0322-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
368 Parmee ER, Sinharoy R, Xu F, Givand JC, Rosen LA. Discovery and Development Of The DPP-4 Inhibitor Januvia™ (Sita-Gliptin). In: Huang X, Aslanian RG, editors. Case Studies in Modern Drug Discovery and Development. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 10-44. [DOI: 10.1002/9781118219683.ch2] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
369 Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658. [PMID: 22675341 DOI: 10.1155/2012/672658] [Cited by in Crossref: 42] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
370 Bourey R, Lambert C. Drug Treatment of Obesity. Obesity 2012. [DOI: 10.1201/b12085-11] [Reference Citation Analysis]
371 Butryn ML, Webb V, Wadden TA. Behavioral treatment of obesity. Psychiatr Clin North Am 2011;34:841-59. [PMID: 22098808 DOI: 10.1016/j.psc.2011.08.006] [Cited by in Crossref: 262] [Cited by in F6Publishing: 275] [Article Influence: 26.2] [Reference Citation Analysis]
372 Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36:13-25. [PMID: 22363917 DOI: 10.4093/dmj.2012.36.1.13] [Cited by in Crossref: 355] [Cited by in F6Publishing: 373] [Article Influence: 35.5] [Reference Citation Analysis]
373 Bloomgarden ZT. American Diabetes Association Postgraduate Meetings--2011. Diabetes Care 2011;34:e164-9. [PMID: 22025788 DOI: 10.2337/dc11-1557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
374 Kinalska I, Bednarska-Chabowska D, Adamiec-Mroczek J, Hak L. The influence of incretin mimetics on cardiovascular risk factors in diabetes. ISRN Endocrinol 2012;2012:625809. [PMID: 22462016 DOI: 10.5402/2012/625809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Hansen G, Jelsing J, Vrang N. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin 2012;33:194-200. [PMID: 22301859 DOI: 10.1038/aps.2011.168] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
376 Zhang ZY, Wang MW. Obesity, a health burden of a global nature. Acta Pharmacol Sin 2012;33:145-7. [PMID: 22301854 DOI: 10.1038/aps.2011.185] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
377 Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin 2012;33:173-81. [PMID: 22301857 DOI: 10.1038/aps.2011.203] [Cited by in Crossref: 184] [Cited by in F6Publishing: 190] [Article Influence: 18.4] [Reference Citation Analysis]
378 Scheen A, Van Gaal L. Médicaments de l’obésité et risque cardiovasculaire. Médecine des Maladies Métaboliques 2012;6:31-37. [DOI: 10.1016/s1957-2557(12)70352-8] [Reference Citation Analysis]
379 Zhao S, Kanoski SE, Yan J, Grill HJ, Hayes MR. Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. Int J Obes (Lond) 2012;36:1522-8. [PMID: 22249232 DOI: 10.1038/ijo.2011.265] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
380 Dowman JK, Newsome PN. The Chronic Liver Disease Patient. Problem‐Based Approach to Gastroenterology and Hepatology 2012. [DOI: 10.1002/9781444346381.ch14] [Reference Citation Analysis]
381 De Silva A, Bloom SR. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut Liver 2012;6:10-20. [PMID: 22375166 DOI: 10.5009/gnl.2012.6.1.10] [Cited by in Crossref: 201] [Cited by in F6Publishing: 207] [Article Influence: 20.1] [Reference Citation Analysis]
382 Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. [PMID: 22236411 DOI: 10.1136/bmj.d7771] [Cited by in Crossref: 570] [Cited by in F6Publishing: 601] [Article Influence: 57.0] [Reference Citation Analysis]
383 Page R. Insulin, other hypoglycemic drugs, and glucagon. A worldwide yearly survey of new data in adverse drug reactions and interactions 2012. [DOI: 10.1016/b978-0-444-59499-0.00042-8] [Reference Citation Analysis]
384 Smith SR. Obesity Therapy. Atlas of Diabetes 2012. [DOI: 10.1007/978-1-4614-1028-7_15] [Reference Citation Analysis]
385 Dennedy MC, Dunne F. Maternal Obesity and Pregnancy. Maternal Obesity and Pregnancy 2012. [DOI: 10.1007/978-3-642-25023-1_7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
386 Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-27. [PMID: 22227019 DOI: 10.1016/j.neuropharm.2011.12.022] [Cited by in Crossref: 185] [Cited by in F6Publishing: 192] [Article Influence: 16.8] [Reference Citation Analysis]
387 Müller JE, Sträter-Müller D, Marks HJ, Gläsner M, Kneppe P, Clemens-Harmening B, Menker H. Carbohydrate restricted diet in conjunction with metformin and liraglutide is an effective treatment in patients with deteriorated type 2 diabetes mellitus: Proof-of-concept study. Nutr Metab (Lond) 2011;8:92. [PMID: 22196251 DOI: 10.1186/1743-7075-8-92] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
388 Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord 2011;12:187-95. [PMID: 21336840 DOI: 10.1007/s11154-011-9170-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
389 Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012;153:647-58. [PMID: 22128031 DOI: 10.1210/en.2011-1443] [Cited by in Crossref: 289] [Cited by in F6Publishing: 305] [Article Influence: 26.3] [Reference Citation Analysis]
390 Garber AJ. Incretin therapy--present and future. Rev Diabet Stud. 2011;8:307-322. [PMID: 22262069 DOI: 10.1900/rds.2011.8.307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
391 Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35:4-16. [PMID: 22048570 DOI: 10.1038/hr.2011.173] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 9.9] [Reference Citation Analysis]
392 Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35:4-11. [PMID: 22040840 DOI: 10.2337/dc11-0931] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 7.7] [Reference Citation Analysis]
393 Folli F, Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 2011;20:1717-22. [PMID: 22017240 DOI: 10.1517/13543784.2011.630660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
394 Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf. 2011;34:641-650. [PMID: 21751825 DOI: 10.2165/11592040-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
395 Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124:2338-2349. [PMID: 22007077 DOI: 10.1161/circulationaha.111.041418] [Cited by in Crossref: 270] [Cited by in F6Publishing: 288] [Article Influence: 24.5] [Reference Citation Analysis]
396 Apovian CM. Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes Metab Syndr Obes 2011;4:353-69. [PMID: 22135499 DOI: 10.2147/DMSO.S24022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
397 Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;:CD006423. [PMID: 21975753 DOI: 10.1002/14651858.CD006423.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 98] [Article Influence: 5.5] [Reference Citation Analysis]
398 Garber AJ. Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease. Endocrine Practice 2011;17:13-9. [DOI: 10.1016/s1530-891x(20)43147-7] [Reference Citation Analysis]
399 Meires J, Christie C. Contemporary approaches to adult Obesity treatment. The Nurse Practitioner 2011;36:37-46. [DOI: 10.1097/01.npr.0000403291.15266.d6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
400 Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. Am J Physiol Regul Integr Comp Physiol 2011;301:R1479-85. [PMID: 21849636 DOI: 10.1152/ajpregu.00356.2011] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
401 Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854. [PMID: 21844879 DOI: 10.1038/ijo.2011.158] [Cited by in Crossref: 393] [Cited by in F6Publishing: 433] [Article Influence: 35.7] [Reference Citation Analysis]
402 Sullivan SD, Ratner RE. Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep 2011;11:91-8. [PMID: 21207204 DOI: 10.1007/s11892-010-0170-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
403 Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67. [PMID: 21232047 DOI: 10.1111/j.1476-5381.2011.01218.x] [Cited by in Crossref: 158] [Cited by in F6Publishing: 172] [Article Influence: 14.4] [Reference Citation Analysis]
404 Powell TM, Khera A. Therapeutic approaches to obesity. Curr Treat Options Cardiovasc Med 2010;12:381-95. [PMID: 20842561 DOI: 10.1007/s11936-010-0080-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
405 DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34 Suppl 2:S202-9. [PMID: 21525456 DOI: 10.2337/dc11-s221] [Cited by in Crossref: 94] [Cited by in F6Publishing: 102] [Article Influence: 8.5] [Reference Citation Analysis]
406 Tripathy D, Defronzo RA. Can we prevent diabetes with a single pill? Diabetes Management 2011;1:355-358. [DOI: 10.2217/dmt.11.35] [Reference Citation Analysis]
407 Dicembrini I, Pala L, Rotella CM. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res 2011;2011:898913. [PMID: 21747834 DOI: 10.1155/2011/898913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
408 Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152:3103-3112. [PMID: 21693680 DOI: 10.1210/en.2011-0174] [Cited by in Crossref: 238] [Cited by in F6Publishing: 251] [Article Influence: 21.6] [Reference Citation Analysis]
409 Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7:507-16. [PMID: 21647189 DOI: 10.1038/nrendo.2011.77] [Cited by in Crossref: 145] [Cited by in F6Publishing: 151] [Article Influence: 13.2] [Reference Citation Analysis]
410 . References. A Guide to Obesity and the Metabolic Syndrome 2011. [DOI: 10.1201/b10790-15] [Reference Citation Analysis]
411 Tinahones FJ. ¿Qué está pasando con los fármacos para el tratamiento de la obesidad? Endocrinología y Nutrición 2011;58:101-103. [DOI: 10.1016/j.endonu.2010.06.005] [Reference Citation Analysis]
412 Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011; 2(2): 19-23 [PMID: 21537456 DOI: 10.4239/wjd.v2.i2.19] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
413 . Type 2 Diabetes: General Introduction. Practical Diabetes Care 2011. [DOI: 10.1002/9781444391152.ch5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
414 Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes 2011;2011:636181. [PMID: 21331293 DOI: 10.1155/2011/636181] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
415 White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40. [PMID: 21300711 DOI: 10.1136/bmj.d40] [Cited by in Crossref: 478] [Cited by in F6Publishing: 527] [Article Influence: 43.5] [Reference Citation Analysis]
416 Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011;60:1-23. [PMID: 21134520 DOI: 10.1016/j.metabol.2010.09.010] [Cited by in Crossref: 185] [Cited by in F6Publishing: 205] [Article Influence: 16.8] [Reference Citation Analysis]
417 Covasa M, Swartz T. The Role of Glucagon-Like Peptide-1 (Glp-1) in Eating Behavior. Handbook of Behavior, Food and Nutrition 2011. [DOI: 10.1007/978-0-387-92271-3_14] [Reference Citation Analysis]
418 Codario RA. Obesity and the Metabolic Syndrome. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome 2011. [DOI: 10.1007/978-1-60327-441-8_5] [Reference Citation Analysis]
419 Klein S, Fabbrini E, Romijn JA. Obesity. Williams Textbook of Endocrinology 2011. [DOI: 10.1016/b978-1-4377-0324-5.00036-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
420 Tinahones FJ. What is happening with antiobesity drugs? Endocrinología y Nutrición (English Edition) 2011;58:101-103. [DOI: 10.1016/s2173-5093(11)70020-4] [Reference Citation Analysis]
421 Sharma AM, Padwal R, Karmali S, W. Birch D. Is it Time to Seriously Target Obesity to Prevent and Control Diabetes? Canadian Journal of Diabetes 2011;35:129-135. [DOI: 10.1016/s1499-2671(11)52010-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
422 Wang Y, Kokkotou E. Gastrointestinal Hormones and Obesity. Metabolic Basis of Obesity 2011. [DOI: 10.1007/978-1-4419-1607-5_6] [Reference Citation Analysis]
423 Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011;28:1792-818. [PMID: 21181547 DOI: 10.1007/s11095-010-0341-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
424 Kahal H, Atkin SL, Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes 2011;2011:402052. [PMID: 21197149 DOI: 10.1155/2011/402052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
425 Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674. [PMID: 21197148 DOI: 10.1155/2011/179674] [Cited by in Crossref: 94] [Cited by in F6Publishing: 112] [Article Influence: 7.8] [Reference Citation Analysis]
426 Stephens JW. The incretin system in the management of type 2 diabetes mellitus. Clin Med (Lond) 2010;10:491-5. [PMID: 21117386 DOI: 10.7861/clinmedicine.10-5-491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med 2010;27:556-62. [PMID: 20536952 DOI: 10.1111/j.1464-5491.2010.02990.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
428 Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther 2010;4:279-90. [PMID: 21116334 DOI: 10.2147/DDDT.S10180] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
429 Cheng V, Kashyap SR. Weight considerations in pharmacotherapy for type 2 diabetes. J Obes 2011;2011:984245. [PMID: 20885921 DOI: 10.1155/2011/984245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
430 Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag 2010;6:401-11. [PMID: 20856686 DOI: 10.2147/tcrm.s7313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
431 Ampudia-blasco F, Calvo Gómez C, Cos Claramunt X, García Alegría J, Jódar Gimeno E, Mediavilla Bravo J, Mezquita Raya P, Navarro Pérez J, Puig Domingo M. Liraglutida en el tratamiento de la diabetes tipo 2:. Avances en Diabetología 2010;26:226-234. [DOI: 10.1016/s1134-3230(10)64003-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
432 Halpern B, Oliveira ES, Faria AM, Halpern A, Melo ME, Cercato C, Mancini MC. Combinations of drugs in the Treatment of Obesity. Pharmaceuticals (Basel) 2010;3:2398-415. [PMID: 27713360 DOI: 10.3390/ph3082398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
433 Neff LM, Kushner RF. Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab Syndr Obes 2010;3:263-73. [PMID: 21437094 DOI: 10.2147/dmsott.s6816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
434 Cada DJ, Levien TL, Baker DE. Liraglutide. Hosp Pharm 2010;45:552-66. [DOI: 10.1310/hpj4507-552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
435 Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 2010;6:444-53. [PMID: 20585346 DOI: 10.1038/nrendo.2010.93] [Cited by in Crossref: 125] [Cited by in F6Publishing: 131] [Article Influence: 10.4] [Reference Citation Analysis]
436 Czernichow S, Batty GD. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts 2010;3:155-6. [PMID: 20616603 DOI: 10.1159/000316508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
437 Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, Izumi T. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010;9:17. [PMID: 20470376 DOI: 10.1186/1475-2840-9-17] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
438 Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, Suryawanshi S, Carofano W, Johnson-Levonas AO, Shapiro DR, Kaufman KD, Heymsfield SB, Amatruda JM. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity (Silver Spring) 2010;18:2301-10. [PMID: 20379151 DOI: 10.1038/oby.2010.67] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
439 Luft FC. The time has come for incretins, a long time coming. J Mol Med 2010;88:319-321. [DOI: 10.1007/s00109-009-0586-5] [Reference Citation Analysis]
440 Edavalath M, Stephens JW. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence 2010;4:61-8. [PMID: 20361006 DOI: 10.2147/ppa.s6358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
441 Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173-1175. [PMID: 20332357 DOI: 10.2337/dc09-1203] [Cited by in Crossref: 148] [Cited by in F6Publishing: 161] [Article Influence: 12.3] [Reference Citation Analysis]
442 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PMID: 20332511 DOI: 10.1136/bmj.c869] [Cited by in Crossref: 3174] [Cited by in F6Publishing: 3466] [Article Influence: 264.5] [Reference Citation Analysis]
443 Dandona P, Chaudhuri A, Dhindsa S. A novel antihypertensive effect of exenatide, a GLP-1 agonist. Am J Hypertens 2010;23:228. [PMID: 20154655 DOI: 10.1038/ajh.2009.271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
444 Hutchinson E. Liraglutide induces weight loss. Nat Rev Gastroenterol Hepatol 2010;7:68-68. [DOI: 10.1038/nrgastro.2009.228] [Reference Citation Analysis]
445 The Expert Weighs In: What are Incretins and What Do They Do?: Interview with Nick Finer, MD. Obesity and Weight Management 2010;6:8-11. [DOI: 10.1089/owm.2010.0102] [Reference Citation Analysis]
446 Freemark M. Pharmacotherapy of Childhood Obesity and Pre-diabetes. Pediatric Obesity 2010. [DOI: 10.1007/978-1-60327-874-4_23] [Reference Citation Analysis]
447 Ness-abramof R. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Yearbook of Endocrinology 2010;2010:108-110. [DOI: 10.1016/s0084-3741(10)79555-x] [Reference Citation Analysis]